MESOBLAST LIMITED
ASX:MSBPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 92.2% of what they think they own, once every option and right converts.
Share count grew 14% in 24 months; 1 cash raise in 24 months; options/rights overhang 8% of shares
MESOBLAST LIMITED's ordinary share count grew 13.7% between April 2024 and July 2026, reaching 1.30B shares. In the past 24 months, the company completed one capital raise, a placement in January 2025, which brought in A$260.0M. Options and rights on issue represent a potential 110M new shares, or 8.5% of the current share count, none of which are in the money at the current share price. An expiry date for these securities has not been filed. As of June 2026, MESOBLAST LIMITED held A$138.8M in available cash, covering approximately 10.2 quarters of operations. One proposed securities issue (Appendix 3B) is pending, with an expected issue date in December 2026.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 24 Aug 2026 | 3G · unquoted | MSB : ORDINARY FULLY PAID | 1.30B | Appendix 3G |
| 20 July 2026 | 2A · quoted issue | MSB : ORDINARY FULLY PAID | 1.30B | Appendix 2A |
| 20 July 2026 | 3G · unquoted | MSB : ORDINARY FULLY PAID | 1.30B | Appendix 3G |
| 14 July 2026 | 3G · unquoted | MSB : ORDINARY FULLY PAID | 1.29B | Appendix 3G |
| 14 July 2026 | 2A · quoted issue | MSB : ORDINARY FULLY PAID | 1.30B | Appendix 2A |
Capital raises
1 cash raise in the last 24 months · 0 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 109.8M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| MSBAP | Warrants | Price-triggered | — | — | 885k | Filing |
| MSBAA | Warrants | Price-triggered | — | — | 2.0M | Filing |
| MSBAB | Warrants | Price-triggered | — | — | 2.0M | Filing |
| MSBAO | Warrants | Price-triggered | — | — | 15.0M | Filing |
| MSBAI | Options | Price-triggered | — | — | 89.9M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 19 Aug 2026 | Philip R. Krause | Other | — | 875k | — | — | 3Y notice |
| 17 July 2026 | Dr Silviu Itescu | Other | 1.9M | 1.9M | — | $2.7M | 3Y notice |
| 7 July 2026 | Dr Silviu Itescu | Other | 79.0M | 18.2M | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.